Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Daniel J. Lippis, a CVP at Edwards Lifesciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel J. Lippis, a Corporate Vice President at Edwards Lifesciences, executed transactions involving the company's stock on December 16, 2024.
• Mr. Lippis exercised 2,500 employee stock options at a price of $45.2767 per share.
• Concurrently, he sold 2,500 shares of common stock at a weighted average price of $74.0783 per share.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on December 11, 2023.
• Following these transactions, Mr. Lippis directly owns 23,189.0651 shares of Edwards Lifesciences common stock.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the medical device industry like Medtronic and Abbott.
• The reported transactions are typical for executives who receive stock options as part of their compensation packages.
• The price range of the stock sale ($73.715 to $74.335) is consistent with the market price of Edwards Lifesciences stock at the time of the transaction.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.

Key Dates

Keywords

insider trading, stock options, Rule 10b5-1, equity securities, beneficial ownership, Edwards Lifesciences, stock sale